Clinical Scorecard: FDA Tentatively Approves Generic Lenacapavir
At a Glance
| Category | Detail |
|---|---|
| Condition | HIV-1 prevention through pre-exposure prophylaxis (PrEP) |
| Key Mechanisms | Lenacapavir is a capsid inhibitor that interferes with multiple stages of HIV replication. |
| Target Population | Adults and adolescents weighing at least 35 kg seeking prevention of sexually acquired HIV-1. |
| Care Setting | HIV prevention and PrEP services; the generic received tentative FDA approval, with access dependent on national regulatory reviews, procurement, funding, and distribution. |
Key Highlights
- The FDA granted tentative approval to Dr. Reddy's generic lenacapavir injection for HIV PrEP.
- The twice-yearly injection is intended to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg.
- Tentative approval does not authorize US marketing while applicable patent protections remain in effect.
- The partnership agreement sets the injectable formulation price at $40 per person annually; Unitaid reported the initial oral loading course is priced at up to $17.
- Efficacy results cited are from trials of Gilead's original formulation, not a separate efficacy trial of Dr. Reddy's generic.
Guideline-Based Recommendations
Diagnosis
- Test for HIV-1 before starting lenacapavir and before each subsequent injection.
Management
- The described PrEP regimen is a twice-yearly injection with an initial oral loading course.
- The FDA-approved prescribing information for lenacapavir carries a boxed warning about drug resistance when used in individuals with undiagnosed HIV-1 infection.
Monitoring & Follow-up
- Common adverse reactions noted include injection-site reactions, headache, and nausea.
Risks
- Use in individuals with undiagnosed HIV-1 infection may lead to drug resistance, according to the boxed warning.
Patient & Prescribing Data
Adults and adolescents weighing at least 35 kg for prevention of sexually acquired HIV-1.
The generic is intended for twice-yearly injection and requires an initial oral loading course. The article reports a partnership price of $40 per person annually for the injectable formulation and up to $17 for the initial oral course.
Clinical Best Practices
- Confirm HIV-1 status before initiating lenacapavir and before each subsequent injection.
- Account for the boxed warning about drug resistance in individuals with undiagnosed HIV-1 infection.
- Distinguish evidence for Gilead's original formulation from evidence specific to the generic; the article reports no separate efficacy trial of Dr. Reddy's generic.
- Consider that availability depends on national regulatory reviews, procurement, funding, and distribution arrangements.
Related Resources & Content
- Clinton Health Access Initiative
- Unitaid
- NEJM: PURPOSE 1
- NEJM: PURPOSE 2
- DailyMed
- FDA PEPFAR FAQs
- FDA PDUFA V Fee Information
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
